Dr. Adrian M. Di Bisceglie
Company: HighTide Therapeutics
Job title: Chief Medical Officer
Seminars:
Learning About the Gut- Liver Axis as a Therapeutic Target in NASH 1:30 pm
• Describing the importance of the microbiome in health and disease • Exploring possible mechanisms by which changes in the microbiome may improve NASH • Understanding the effects of HTD1801 on human NASH – possible actions via microbiome Adrian M. Di Bisceglie, Chief Medical Officer, HighTide TherapeuticsRead more
day: Day 1 Stream 1 PM